Ratio Therapeutics
@Ratio_TxThe Partner of Choice for Next-Generation Radiopharmaceutical Precision Medicine
Similar User
@Triumvirainc
@Halia_Tx
@FibroBiologics
@AmpersandBio
@erica_fiorini
@MattJPurcell
@ItachoGR
@TonyJRusso
@elioscience
@P41CMITT
.@ky_lahucik of @Endpts spoke with Ratio about the exciting collaboration agreement with @Novartis Read here for additional insights into this deal: endpts.com/novartis-strik… #radiotherapeutics #biopharma #news
Today, Ratio is pleased to announce it entered into an exclusive worldwide license and collaboration agreement with @Novartis for the development of a Somatostatin Receptor 2 (SSTR2) radiotherapeutic candidate. prnewswire.com/news-releases/… #radiopharmaceuticals #biotech #news
A recent report shows that the global #radiopharma market is on track to reach $26.5 billion by 2031. At Ratio, we're at the forefront of this growing field, developing therapies with life-changing potential. Read in @PharmExec to learn more: pharmexec.com/view/report-ra…
November is #PancreaticCancerAwarenessMonth. This month, we stand in solidarity with patients, survivors, and their families in the fight against pancreatic cancer.
#ICYMI – @BioPharmaDive recently featured Ratio in this article from Michael Gibney about today’s radiopharma boom. Full article: biopharmadive.com/news/radiophar… #radiopharmaceuticals
Next week, Ratio’s CSO, Dr. John Babich will participate in a virtual roundtable to discuss FAP-targeted PET imaging & theranostics. Hosted by @endpts, the webinar will take place on November 7, 2024 at 11 am ET. webinars.endpts.com/fapi-pet-imagi…
Ratio is proud to be recognized by @bostinno and @bosbizevents in this year’s BostInno Fire Awards. See the full list of #INNOFIRE honorees: bizjournals.com/boston/inno/st…
Check out this article from @ConferenceForum to learn about the potential for combining radiopharmaceuticals with immuno-oncology for enhanced cancer therapy. theconferenceforum.org/editorial/what… #radiopharmaceuticals #immunooncology
Today we want to spotlight @ZEROCancer and their dedication to supporting prostate cancer patients, families, and caregivers through advocacy and education. For anyone recently diagnosed with prostate cancer, ZERO is an excellent place to start. zerocancer.org
Ratio team members Dr. Jacob Hesterman and Dr. Shawn Hillier will be presenting ePosters at the European Association of Nuclear Medicine (EANM) 2024 Congress, taking place in Hamburg, Germany on October 19-23, 2024. For more information visit: eanm24.eanm.org #EANM24
#DYK that 1 in 8 women will develop breast cancer in their lifetime? Early detection and treatment are key to beating the disease. This October, remember to speak to your doctor about applicable cancer screenings and when to get a mammogram.
Ratio is pleased to welcome John Marquis, PhD, as our new Vice President Discovery Program Integration! Dr. Marquis brings a proven track record of driving the direction and progress of scientific teams to define and develop therapeutic candidates. Welcome aboard the Ratio team!
Thank you to Michael Gibney for featuring Ratio in @PharmaVoice! Our CEO Jack Hoppin shares insights on the ‘radio-renaissance’ and why radiopharmaceuticals are gaining momentum, with smaller companies driving innovation. Check out the full article here pharmavoice.com/news/radiophar…
Next week, Dr. Matthias Friebe, CTO, will be delivering a seminar at the upcoming 2nd Annual TRP Supply Chain & Manufacturing Summit, taking place September 24-26, 2024 in Boston, MA. Register today: …opharma-supplychain-manufacturing.com #radiopharmaceuticals #conference #TRP
Positive momentum in the field continues with @Novartis’ $200 million investment two #radiopharmaceuticals manufacturing facilities. A rising tide lifts all boats! Learn more from @statnews: statnews.com/2024/09/04/nov…
Ratio team members Dr. Jacob Hesterman, CDO, and Dr. Caitlin McCutcheon, Senior Research Associate, will be leading a webinar in collaboration with @ScinticaInst on September 18, 2024, at 12 PM ET. Register here: scintica.com/events/gamma-e…
Dr. Shawn Hillier, Ratio’s Head of Preclinical Development, will be presenting at the Translational Oncology Symposium on September 17, 2024. Register here: championsoncology.com/boston-symposi… #Radiopharmaceuticals #Cancer #TranslationalOncology
Ratio’s Macropa™ technology reflects a proprietary chelator that is used to attach the alpha emitting radionuclide actinium-225 to Trillium™ and other compounds. Its unique chemistry enables ease of manufacturing and improves in vivo stability. ratiotx.com
This #ProstateCancerAwarenessMonth, take charge with regular screenings, a balanced diet, and staying active—key steps in preventing prostate cancer. Early detection matters! We're proud to support this mission with best-in-class #radiopharmaceuticals. bit.ly/3MiHtwy
Exciting news in #radiopharma. Telix's NDA for TLX101-CDx, a PET imaging agent for gliomas, marks a big step in brain #cancer diagnostics. At Ratio, we're encouraged by the potential of radiopharmaceuticals to improve diagnosis and treatment decisions. bit.ly/4e3LVej
United States Trends
- 1. $CUTO 6.597 posts
- 2. #tuesdayvibe 3.358 posts
- 3. #GMMTV2025 3,06 Mn posts
- 4. Bill Gates 40,6 B posts
- 5. Good Tuesday 32,5 B posts
- 6. HOBI 166 B posts
- 7. #DeFi 32,2 B posts
- 8. Canada 436 B posts
- 9. #AsWeAre_WithSeungmin 6.306 posts
- 10. #26Nov 3.261 posts
- 11. Happy Thanksgiving 22,6 B posts
- 12. Tariffs 146 B posts
- 13. Hangovers N/A
- 14. Alec Baldwin 5.840 posts
- 15. Cutoshi N/A
- 16. Irene 308 B posts
- 17. Toyota 29,7 B posts
- 18. hoseok 62,4 B posts
- 19. Pitchfork 3.985 posts
- 20. Buy American 4.659 posts
Who to follow
Something went wrong.
Something went wrong.